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1. Introduction 
Joint diseases cause serious medical problems for several million people world-wide and 
therefore the World Health Organization has designated years 2000-2010 as the Decade of 
the Bone and Joint (Popko et al.2011). 
Osteoarthritis (OA) is the most common, and increasingly prevalent, human joint disorder 
(Dieppe, 2000). It has been estimated that in 1990 12 % of Americans, nearly 21 million 
people had clinical symptoms of osteoarthritis (Lawrence et al., 1998). 
Rheumatoid arthritis (RA) affects about 0.3 to 1.5% of the world population(Chikanza et.al., 
1998). Juvenile idiopatic arthritis (JIA) is one of the most common rheumatic diseases in 
children, which causes pain and functional disability. According to a 2008 study performed 
by the National Arthritis Data Workgroup, there were close to 3000,000 children in the 
U.S.A. with some form of juvenile arthritis (Giannini et al., 2010). 
Lyme arthritis (LA) caused by spirochete Borrelia burgdorferi, is increasing in prevalence 
disease involving the musculoskeletal system, particularly affecting knee joints (Pancewicz 
et. al.2009).  
RA and JIA are chronic autoimmune inflammatory diseases primarily affecting the synovial 
membrane, leading to joint damage and destruction. OA is the most common joint disorder 
and a major public health problem in western populations (Lawrence et al. 1998). 
Clinical and epidemiological studies on OA have recognized a series of etiologic factors 
including local factors (such as malformations or joint injuries) and systemic factors (such as 
overweight, race, gender, or metabolic diseases). OA is associated with a loss of proper 
balance between synthesis and degradation of the macromolecules that gives articular 
cartilage its biomechanical and functional properties. Concomitantly in OA, changes occur 
in the structure and metabolism of the synovium and subchondral bone of the joint.  
2. Degradation of human articular cartilage 
Progressive destruction of articular cartilage is a common feature of OA, RA, and LA. The 
articular cartilage from patients with OA and RA has decreased concentrations of 
proteoglycans and glycosaminoglycans (GAGs), and the size of GAG molecules is also 
www.intechopen.com
 Rheumatoid Arthritis – Etiology, Consequences and Co-Morbidities 
 
98
reduced (Inerot et al.1978). In established joint disease, loss of articular proteoglycans could be 
more significant than the collagen loss (Mankin & Lippiello, 1970; Popko et al. 1983). 
Destruction of articular cartilage is a multifactorial process, which is performed extracellularly 
by concerted action of matrix metalloproteinases (MMPs) and glycosidases (Fig.1). 
 
 
Fig. 1. Cartilage destruction by proteases and glycosidases. 
Of the metalloproteinases, collagenase (MMP-1) in particular, appears to be responsible for 
the degradation of interstitial collagens. The gelatinases (MMP-2 and MMP-9) degrade the 
denatured forms of collagens, acting in synergy with MMP-1. The stromelysins (MMP-3) 
have broader substrate specificity for non-connective tissue proteins. Membrane-type MMPs 
(MT-MMP-1 and MT-MMP-3) have been detected at sites of destruction in rheumatoid 
arthritis (Pap et al., 2000). 
Protease action increases the accessibility of cleavage sites for endo- and exoglycosidases 
(Ortutay et al. 2003) by production glycopeptides (Fig.1). 
Endoglycosidases (hyaluronidases, chondroitinases, keratanases,etc.) cleave glycosidic 
linkages inside glycosaminoglycan or oligosaccharide chains of the proteoglycans or release 
oligosaccharide chains from protein cores ( Stypułkowska et al. 2004).  
In contrast to endoglycosidases, lysosomal exoglycosidases: N-acetyl-ǃ-hexosaminidase 
(HEX), ǃ-galactosidase (GAL), ǃ-glucuronidase (GluA), ǂ-mannosidase (MAN) and ǂ-
fucosidase (FUC), release monosaccharides from the non-reducing terminals of 
oligosaccharide chains of glycoproteins, glycolipids and proteoglycan glycosaminoglycans 
of synovial tissue, articular cartilage and synovial fluid. N-acetyl-ǃ-hexosaminidase (HEX) is 
present as two isoenzymes HEX A and HEX B which both release terminal N-
acetylhexosamines, whereas HEX A also hydrolyzes hexosamines in acidic oligosaccharides 
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as in GM2 gangliosidases ( Zwierz et al. 1999; Pennybacker et al. 1996; Sharma et al. 2003; 
Itakura et al. 2006 ). ǃ-galactosidase (GAL) releases terminal galactose (Czartoryska 1977), 
from the non reducing terminal of oligosaccharide chains of glycoproteins, glycolipids and 
keratan sulfate. Mannose is liberated from N-linked sugar chains of glycoproteins, as well as 
a variety of synthetic and natural ǃ-mannosides, by ǂ-mannosidase (MAN) (Czartoryska 
1977). Lysosomal ǂ-fucosidase (FUC) ) (Li,C.,Qian et al. 2006) is involved in the degradation 
a variety of fucose-containing oligosaccharide chains of glycoproteins and glycolipids and ǃ-
glucuronidase (GluA) cleaves glucuronic acid residues from the non-reducing terminal of 
glycosaminoglycans (GAGs) (Marciniak et al. 2006). 
3. The characterization and function of lysosomal glycosidases  
The main exoglycosidases in tissues, serum and synovial fluid of humans are:  
N-acetyl-ǃ-hexosaminidase (HEX), ǃ-glucuronidase (GluA), ǃ-galactosidase (GAL), ǂ-
mannosidase (ǂ-MAN), and ǂ-fucosidase (FUC). N-acetyl-ǃ-hexosaminidase (EC 3.2.1.52, 
HEX, NAG) is the most active enzyme of the lysosomal exoglycosidases (Popko et al. 2006). 
HEX has several isoenzymes: A, B, S, C, I1, I2. HEX A and S are thermolabile and B, P, I1, I2, 
thermostable. In humans there are two major isoenzymes of hexosaminidase: HEX A (ǂǃ), 
and HEX B (ǃǃ). Both isoenzymes recognize terminal N-acetylglucosamine and N-
acetylgalactosamine, but only HEX A recognizes 6-sulfated residues of these sugars. HEX A 
represents (an average) 48% of total HEX activity in serum, and 52% of total HEX activity in 
synovial fluid (Popko et. al.2006). 
The hexosaminidase S (HEX S) is of minor importance, as it constitutes less than 0.02% of 
HEX activity (Ikonne et al. 1975)), and can be detected in patients with Sandhoff disease 
(Yamanak et al. 2001). The function of the HEX S is not well understood, but it is probably 
involved in the degradation of GAGs. 
The protein moiety of lysosomal exoglycosidases is synthesized in the rough endoplasmic 
reticulum, and transported to lysosomes thought the endoplasmatic reticulum and Golgi 
apparatus (Zwierz et al.1999). Some of the lysosomal enzymes are secreted from the cell into 
the extracellular fluid. Another route for the secretion of lysosomal enzymes is from the 
lysosomes via the endosomes and Golgi compartment to the cell surface and extracellular 
fluid. The release of exoglycosidases is regulated by a small Ras-related GTP-binding 
protein Rho p21 (Rho proteins control the polymerization of actin into filaments and govern 
the organization of body filaments into specific types of structures). The release of 
exoglycosidases from mast cells has shown to be induced by an IgE mediated increase in 
intracellular Ca²+ (Zwierz et al. 1999). 
Exoglycosidases activity of knee synovial fluid and serum of healthy humans is presented in 
Fig. 2. 
The exoglycosidases activity, is higher in synovial fluid than in serum. Levels of the HEX 
activity are constant in serum of healthy humans up to 40 years of age, whereas in older 
people (more than 40 years of age) the level of HEX activity significantly increases. 
The substrates for exoglycosidases in articular cartilage include cell surface and extracellular 
matrix glycoproteins as well as glycosaminoglycans: chondroitin 4-sulfate, chondroitin 6-
sulfate, hyaluronic acid, keratin sulfate, and dermatan sulfate (Winchester 1996; Stypułkowska 
et al. 2004). 
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Fig. 2. Activity of exoglycosidases (nmol/ml/min) in synovial fluid and serum of healthy 
humans. 
Exoglycosidases degrade glucoconjugates within the lysosome at an optimum pH ranging 
from 4.3 to 5.5 (Zwierz et. al. 1989; Marciniak et. al. 2006). Investigation of the pH 
dependence showed that HEX is active at pH 4.2 to 5.6 with optimum at pH 4.7, and ǃ-
glucuronidase is active between pH 3.4 and 5.6, with optimum activity at pH 4.5 (Marciniak 
et al. 2006).  
 
 
 
Fig. 3. Typical knee of a patient with RA. Showing destruction areas of articular cartilage 
and hypertrophy of synovial membrane. 
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4. The localization of exoglycosidases in joint tissues 
Pugh and Walker (Pugh 1961), using histochemical techniques, reported that the source of 
HEX activity in synovial fluid is from cells of the synovial membrane. Others (Shikhman et 
al. 2000; Ortutay et. al. 2003) have suggested that chondrocytes of RA patients activated by 
IL 1ǃ (interleukin-1ǃ) may be a source of HEX activity in synovial fluid. Relating to this, it 
has been observed that damage to the joint reduces the volume of cartilage and increases a 
proliferation of synovial membrane (Fig. 3).  
Profiles of the exoglycosidases in the synovial membrane of the knee joint of patients with 
RA, JIA and a control group are presented in Fig. 4. 
 
 
Fig. 4. The activity of exoglycosidases in the synovial tissue of the knee joint of patients with 
RA and JIA. 
Normal and inflamed synovial tissues have similar patterns of exoglycosidases activity with 
a significant predominance of HEX activity (Popko et.al.2006). HEX activity in the synovial 
tissue of RA and JIA patients was approximately 10-fold higher than in the synovial tissue 
of the reference group. The increase in activity of GluA, GAL, MAN and FUC in synovial 
tissue of RA and JIA patients (in comparison with reference groups) was moderate, i.e. no 
more than doubled. 
Synovial fibroblast-like cells and chondrocytes may be regarded as a source of mediators of 
joint destruction in RA and JIA. Synoviocytes and chondrocytes secrete proteolytic enzymes 
and exoglycosidases, especially HEX, that are crucial for the degradation of cartilage. The 
destructive phenotypes of the synovial fibroblasts-like cell and chondrocytes in RA are 
probably regulated by inflammatory cytokines released by the pannus connected to the 
cartilage. 
www.intechopen.com
 Rheumatoid Arthritis – Etiology, Consequences and Co-Morbidities 
 
102 
The high activity of exoglycosidases in synovial tissue of RA and JIA patients (Popko et 
al.2006) suggest the value of synovectomy in treatment of rheumatoid diseases (Fig. 5). 
 
 
Fig. 5. Arthroscopic synovectomy a knee of patient with JIA. 
We recommend the usefulness of synovectomy in patients with RA and JIA, as the removal 
of diseased synovial tissue (Fig. 5) could slow down the destructive process of the joint 
cartilage, and allow regeneration of a normal synovial membrane.  
5. Exoglycosidases activity in cell cultured synoviocytes 
The patterns of compartmental distribution of exoglycosidases activity in cultured synovial 
cells of RA and JIA patients are presented in Fig. 6. 
The activity of HEX (total), HEX A, and Glu A in the intracellular compartment in cultured 
synoviocytes of RA and JIA patients is over 3-fold higher than in the extracellular 
compartment. In contrast, no activity of GAL, MAN and FUC in the extracellular 
compartments of these cultured synoviocytes was detectable. It is most likely that these 
exoglycosidases were released extracellularly in small quantities, i.e. below the limits of 
detection of our colorimetric procedure. Shikhman et al. (2000) have demonstrated similar 
results in cultured human articular chondrocytes. The high level of activity of 
exoglycosidases in the intracellular compartment of cultured synoviocytes indirectly 
confirms the suggestion that the degradation of glycosaminoglycans predominantly takes 
place in the intracellular compartment. However, Woynarowska et al. (1992) reported data 
indicating the contribution of extracellular HEX activity in glycosaminoglycan degradation. 
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Fig. 6. Exoglycosidases activity of RA/JIA synovial fibroblast in the intra (In) / extracellular 
(Ex) compartment, expressed as pKat/3-5x105 cells. 
IL-1 and TNF-ǂ (tumor necrosis factor-ǂ) are key proinflammatory cytokines whose 
concentration significantly increases in rheumatoid synovial fluid and joint tissues. 
We have established a profile of exoglycosidases in cell cultures stimulated by IL-1ǃ of 
inflamed (RA, JIA), and post-injury human synoviocytes (Popko et al. 2008) (Fig. 7).  
Stimulation by IL-1ǃ cultured synoviocytes taken from patients with ACL, JIA and RA 
causes much higher increases in activity of HEX and HEX A than remaining exoglycosidases 
(Fig. 7). On Fig. 7 one can see that the increase in HEX activity after IL-1ǃ stimulation is 
more pronounced in the intracellular compartment of synoviocytes derived from 
rheumatoid patients than in ACL-injury, amounting 189.44 % increase (in comparison to 
untreated cultures) in synoviocytes from JIA, and 127.97 % in synoviocytes of RA patients. 
We noted a 201.18 % increase in HEX-A activity (in comparison to untreated cultures) in 
stimulated synoviocytes from JIA, and a 128.03 % increase in synoviocytes of patients with 
RA. In extracellular compartment of cultured rheumatoidal synoviocytes, stimulation by IL-
1ǃ cause only 33.4-72.44 % increases in HEX and HEX A activities. In extracellular 
compartment of cultured synoviocytes derived from injured knees of ACL patients, after 
stimulation by IL-1ǃ the highest increase (121.80 %) was observed in HEX A activity. The 
mechanism of selective stimulation of HEX by IL-1ǃ is not known. Shikhman et al. (2000) 
suggested that cytokines are involved in secretion of HEX from chondrocytes and stated 
that IL-1ǃ could selectively up-regulate HEX synthesis and facilitate intra-compartmental 
transport of HEX from lysosomes/endosomes into the extracellular space, by modifying the 
mannose-6-phosphate receptor system. 
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Fig. 7. Effect of interleukin 1ǃ (IL-1ǃ) on intra-(In) and extracellular (Ex) activity of 
lysosomal exoglycosidases in cultured human synovial cells from patients with anterior 
cruciate ligament (ACL) injuries, juvenile idiopathic arthritis (JIA), and rheumatoid arthritis 
(RA). Synoviocytes were stimulated with IL-1ǃ for 24h at 37ºC. After IL-1ǃ stimulation, 
cultured cells and exracellular fluid were analyzed for exoglycosidase activities. The effect 
of IL-1ǃ was expressed as the enzymatic activity in stimulated versus unstimulated cultures. 
Rheumatoid synoviocytes exhibit altered morphology and show certain similarities to 
tumor cells (Mor et al. 2005). Our data confirmed the observation that synoviocytes obtained 
from patients with JIA and RA are more active in the synthesis and secretion of 
exoglycosidases than those obtained from patients with injured knees or healthy joints 
(Popko et. al.2008). (Popko et. al.2008).  
6. Activity of lysosomal exoglycosidases in serum and synovial fluid of 
patients with RA and JIA 
Information concerning the activity of exoglycosidases in patients with joint diseases is 
ambiguous and limited to a few, mostly old, publications (Bartholomew 1972; Stephens et 
al.1975; Ganguly et al. 1978; Berenbaum et al. 2000; Sohar et al. 2002). Serum HEX activity 
was higher in 35 % of the RA patients than in healthy controls (Berenbaum et al. 2000). 
Berenbaum et.al. (2000) found that the serum HEX concentration was significantly higher in 
destructive RA than in inflammatory RA. Since RA patients with high serum HEX activity 
have more erosions, than those with inflammatory RA, but have no differences in CRP 
levels, it is possible that HEX is a marker of erosions. 
Lysosomal enzymes in human polymorphonuclear leukocytes are ubiquitous, biologically 
active molecules, that can degrade macromolecules such as proteins, glycosaminoglycans, 
nucleic acids, and lipids (Sohar et al.2002). Sohar et.al. (2002) have suggested that the 
increase of HEX activity in the serum of RA patients may be caused by an increase in HEX 
www.intechopen.com
 Lysosomal Glycosidases in Degradation of Human Articular Cartilage 
 
105 
activity of RA leukocytes. Patients with long-standing RA had higher activity of lysosomal 
glycosidases in their leukocytes than those with disease of shorter duration. 
We suggest that of the exoglycosidases, only HEX activity measurement in synovial fluid 
and serum has practical value (Popko et. al. 2006). The specific activity of HEX and its 
isoenzyme A in serum and synovial fluid from patients with different arthropathies is 
presented in Fig. 8.  
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Fig. 8. Specific activity of N-acetyl-ǃ-hexosaminidase and its isoenzyme A in serum and 
synovial fluid (µkat/kg of protein).  
In the serum of RA patients, the specific activity of HEX was significantly increased in 
comparison to control (Fig. 8). This increase of HEX activity in the serum of RA patients may 
depend on the increase in HEX activity of RA leukocytes (Sohar et al. 2002). In the serum of 
patients with JIA and OA, we observed a moderate increase in HEX activity, i.e. 25.46% and 
17.3 % respectively. In the case of patients with ACL injury, the specific activity of HEX and 
its isoenzymes in serum behaved similarly as in the control. 
In the synovial fluid of JIA and RA patients, we found a significant increase in the specific 
activity of HEX and its isoenzymes, in comparison to HEX activity in synovial fluid from 
OA and ACL injuries. This suggests that release of HEX to synovial fluid is greatly 
enhanced by the autoimmunological inflammatory process in knee joint cavity. 
The activity of HEX in synovial fluid of patients with JIA and RA was significantly higher 
than the activity in OA and ACL patients. Additionally, we have found that in JIA and RA 
patients, the specific activity of HEX in synovial fluid is 6-8 times higher than in serum 
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from the same patients. This results suggest that HEX in synovial fluid derives mainly 
from articular tissues or articular leukocytes and not from serum. Therefore, activity of 
HEX in synovial fluid better reflects the situation in the joint cavity than activity of HEX 
in serum.  
The differences between specific activities of HEX (activities calculated per 1 kg of protein) 
in synovial fluid of RA and JIA patients in comparison to OA and ACL patients (Fig. 9) are 
even more evident than differences in concentration of HEX (activities calculated per 
volume of synovial fluid) in the same situations.  
 
 
Fig. 9. The specific activity of HEX in synovial fluid of patients with rheumatoid arthritis. 
Significant increase of specific HEX activity in synovial fluid of JIA patients (in comparison to 
OA and control) may be of diagnostic value in children with prolonged exudates in the knee 
joint, who are resistant to pharmacological and physiotherapeutical treatment. In these cases 
we advise determining specific activity of HEX in the synovial fluid, where values above 10-13 
µkat/kg of protein suggest rheumatoid disease. It is worthy of note that specific activity of 
HEX in synovial fluid of patients with RA demonstrates a broad standard deviation which 
probably depends on destructive or inflammatory processes in the joint. However, 
significantly elevated HEX activity indicated an inflammatory or autoimmunological process 
within the joint.  
7. Assay of exoglycosidase activity 
Samples of the synovial fluid are easily taken from the knee joints during diagnostic or 
therapeutic arthrocentesis or at arthroscopy. Synovial fluid is aspirated from a lateral 
infrapatellar approach with a 21G needle (Fig. 10).  
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Fig. 10. Synovial fluid aspiration from the knee. 
To obtain reliable results of exoglycosidase determinations, patients with inflammatory 
arthritis should avoid steroid drug treatment at the time of arthrocentesis, and for two days 
before arthrocentesis. About 1 ml of synovial fluid is sufficient for assays of exoglycosidase 
activity and protein concentration. Samples of synovial fluid are collected in plastic tubes 
and centrifuged at 10,000x g for 30 min, separated from the cell pellet, and stored at -70º C 
before use. As substrates for exoglycosidase activity we use p-nitrophenyl derivatives of 
appropriate sugars purchased from Sigma, St.Louis, Mo, USA (HEX, GAL, MAN, FUC), and 
Fluka Chemie GmbH (GluA). 
The activities of HEX (E.C. 3.2.1.52), ǃ-glucuronidase (E.C. 3.2.1.31), ǃ-galactosidase (E.C. 
3.2.1.23), ǂ-mannosidase (E.C. 3.2.1.24), and ǂ-fucosidase (E.C. 3.2.1.51) are determined by 
simple and inexpensive methods (Marciniak et. al. 2006). Before exoglycosidases 
determinations, the samples of synovial fluid are diluted with 0.1 M of the appropriate 
buffer and incubated with excess of substrate for 60 min at 37º C. The reaction is stopped by 
adding 0.2 M borate buffer, pH 9.8. HEX A activity is calculated as the difference between 
the total HEX activity and HEX B activity. 
Spectrophotometric measurements of released 4-nitrophenol were carried out at 405 nm 
using a microplate reader Elx800TM. The concentration of enzymatic activity of the 
appropriate exoglycosidase was expressed as nanomoles of p-nitrophenol released per 
minute per ml in synovial fluid and specific activity was expressed in µkat/kg of proteins of 
synovial fluid. The concentration of exoglycosidase activity indicates the ability of the 
specified volume of synovial fluid to release the quantity of monosaccharide indicated. The 
specific activity relates a particular exoglycosidase activity to total protein concentration, 
and shows the proportion of exoglycosidase protein to the total protein content of an 
articular sample of synovial fluid. 
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8. Conclusions 
Although many publications (Shinmei et al. 1992; Lohmander et al. 1995; Saxne & Heinegard 
1995; Myers 1999; Ortutay et al. 2003) have described increased release of markers of 
cartilage, bone, and synovial metabolism into joint fluid, serum, and urine in rheumatoid 
arthritis, the significance of several of these markers remains elusive. Up to now, no markers 
have yet been formally validated to monitor rheumatoid diseases of the joints. We 
hypothesize that determining HEX activity in the synovial fluid of patients with suspected 
idiopatic juvenile arthritis has diagnostic value. Elevation of HEX activity in synovial fluid 
to greater than 10 µkat/kg of protein, suggests rheumatoid disease. 
Despite its huge public health impact, the conservative treatment of joint diseases, 
particularly of OA, is limited to a few types of medication which provide primarily 
symptomatic relief. Inhibition of hexosaminidase activity may represent a potentially novel 
strategy for treating RA and OA. Liu et al. (2001) have synthesized and investigated a series 
of iminocyclitols designed as transition-state analogue inhibitors of extracellular human 
hexosaminidase. Our team (Olszewski et al. 2010) is focusing on pyrimethamine which 
contributes to the regulation of HEX gene expression in synovial cells.  
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